[分享]应用活体成像技术进行抗脑肿瘤药物的疗效评价的一篇文献（PNAS）

Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13513-8. Epub 2003 Oct 31.
  
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors.

Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, Kieran MW, Luster AD, Segal RA.

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

The vast majority of brain tumors in adults exhibit glial characteristics. Brain tumors in children are diverse: Many have neuronal characteristics, whereas others have glial features. Here we show that activation of the Gi protein-coupled receptor CXCR4 is critical for the growth of both malignant neuronal and glial tumors. Systemic administration of CXCR4 antagonist AMD 3100 inhibits growth of intracranial glioblastoma and medulloblastoma xenografts by increasing apoptosis and decreasing the proliferation of tumor cells. This reflects the ability of AMD 3100 to reduce the activation of extracellular signal-regulated kinases 1 and 2 and Akt, all of which are pathways downstream of CXCR4 that promote survival, proliferation, and migration. These studies (i) demonstrate that CXCR4 is critical to the progression of diverse brain malignances and (ii) provide a scientific rationale for clinical evaluation of AMD 3100 in treating both adults and children with malignant brain tumors.

本文免费，下载地址如下：

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=263845